Stay updated on Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.

Latest updates to the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check44 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2 on the page.SummaryDifference0.1%

- Check52 days agoChange DetectedMinor revision update from v3.4.0 to v3.4.1 with no changes to study details or content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check74 days agoChange DetectedThe page shows a new revision label 'Revision: v3.3.4' replacing the previous 'Revision: v3.3.3'. This is a minor technical update with no impact on the study information.SummaryDifference0.1%

- Check95 days agoChange DetectedA consolidated Locations section listing Arizona, Florida, and Minnesota was added, while the prior Arizona/Florida/Minnesota location subsections were removed; the page revision was updated to v3.3.3.SummaryDifference0.4%

Stay in the know with updates to Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.